Kai Tsao, MD, on Smoking Cessation in Patients with Cancer

Video

Given that smoking is one of the major risk factors for recurrence of any cancer, Tsao explained that it's crucial that providers focus on smoking cessation in patients with cancer.

The Ruttenberg Treatment Center is one of several Mount Sinai cancer treatment sites that have begun a National Cancer Institute-funded smoking cessation program for all patients with cancer who answer yes to smoking or second-hand smoke questions during their intake appointment.

With the advent of this new program, patients who fit the aforementioned description will immediately be given state smoking cessation program information or placed into the Mount Sinai cessation program.

Given that smoking is one of the major risk factors for recurrence of any cancer, programs which promote smoking cessation may be particularly important for successful cancer treatment. In an interview with CancerNetwork®, Kai Tsao, MD, medical director of the Ruttenberg Treatment Center at the Tisch Cancer Institute at Mount Sinai and the program’s primary investigator, explained the importance of focusing on smoking cessation in patients with cancer and what programs like that offered at Mount Sinai can offer patients and health care providers.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Related Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.
Related Content